Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06512389
Active, not recruiting Phase 2

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

NCT06512389 · tracked via the Priya Life Science Canada tracker
Phase
Phase 2
Started
2024-08-16
Last updated
2026-09-16

Condition(s) studied

Alcohol Use Disorder

Investigational drug(s) / intervention(s)

Oral solution

Oral solution: 300 mg taken morning and evening

Study summary

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Meets DSM-5 criteria for AUD. * Meets drinking criteria of average weekly consumption \> 10 standard drinks for women and \> 15 standard drinks for men over the past 90 days. * Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol * Agrees not to use cannabis or illicit drugs during the study period. * Able to communicate and provide informed consent in English. * Alanine Aminotransferase (ALT) and Aspartate Transaminase (AST) level should not be more than 2 times the upper normal limit, and bilirubin should not be more than 1.5 times the upper normal limit. * Enrolled in the Ontario Health Insurance Plan (OHIP) * Willing and able to safely abstain from alcohol for at least 12 hours prior to the eligibility and alcohol self-administration visit. * Individuals who are capable of becoming pregnant: agree to the use of highly effective contraception during study participation and for an additional 28 days after the end of cannabidiol administration. Exclusion Criteria: * Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment * History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens * Any history of seizures * Serious unstable medical condition, including severe hepatic abnormalities * Having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study * Current medical conditions, prescriptions, or over the counter medications that interfere with receiving the study drug or alcohol (based on the study physician's assessment) * Severe mental illness (e.g. active psychosis with ongoing delusions and/or hallucinations, active manic or hypomanic episodes, evidence of a major neurocognitive disorder, etc.) and other substance use disorders (moderate or severe; excluding tobacco use disorder) as determined by the qualified investigator * Experiencing active suicidal ideation within the past 1 month and/or suicide attempt within the past 6 months * Recent recreational drug use (assessed via urine toxicology screen) other than alcohol and nicotine products * Current use of CBD products or use of CBD products within the past month. * History of hypersensitivity to CBD * Self-report of significant alcohol-induced flushing after 1-2 drinks (a proxy for aldehyde dehydrogenase deficiency) * Currently pregnant or breastfeeding or intending to become pregnant or breastfeed. * Currently institutionalized which refers to a person who lives in an institutional collective dwelling, such as a hospital, nursing home or prison, including a resident under custody (e.g., patient or inmate). * Currently in treatment for AUD (e.g. Alcoholics Anonymous, group therapy, individual therapy, on anticraving medication)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre for Addiction and Mental Health Toronto Ontario

More Centre for Addiction and Mental Health trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06512389 on ClinicalTrials.gov ↗ ← All trials in Canada